Abby Hardy, Author at BioTuesdays

Executive Moves

Salarius Pharma names Scott Jordan as CBO; Mark Rosenblum as EVP finance and interim CFO

Salarius Pharmaceuticals (NASDAQ:SLRX) has appointed Scott Jordan as chief business officer (CBO) and Mark Rosenblum as EVP finance and interim CFO. Mr. Jordan has been Salarius’ CFO since 2016. As CBO, he will lead...

September 13, 2019

Developments

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease characterized by chronic blistering of...

September 13, 2019

Executive Moves

Adamas Pharma names Neil McFarlane as CEO

Neil McFarlane Adamas Pharmaceuticals (NASDAQ:ADMS) has appointed Neil McFarlane as CEO and a member of its board, effective Sept. 16. Gregory Went, Adamas’ founder, chairman and CEO, will transition to a strategic...

September 13, 2019

Feature

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Closely-held Interface Biologics is selling its Endexo surface modification business and shifting its focus to its Epidel drug delivery technology, initially for ophthalmic indications.

September 3, 2019

Developments

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet...

August 30, 2019

Markets

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

Stifel upgraded Tabula Rasa HealthCare (NASDAQ:TRHC) to “buy” from “hold” and raised its price target to $75 from $70, citing an “improving risk/reward with a favorable fundamental backdrop.” The stock closed at $57.64...

August 30, 2019

Markets

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...

August 26, 2019

Markets

Dawson James starts Athersys at buy; PT $11

Dawson James Securities launched coverage of Athersys (NASDAQ:ATHX) with a “buy” rating and $11 price target. The stock closed at $1.40 on Aug. 23. “Athersys has the potential to change the treatment paradigm for...

August 26, 2019

Developments

Eiger gets FDA breakthrough therapy designation for HDV drug candidate

Eiger BioPharmaceuticals’ (NASDAQ:EIGR) peginterferon lambda (lambda) received FDA breakthrough therapy designation for the treatment of hepatitis delta virus (HDV) infection. HDV is the most severe form of human viral...

August 21, 2019

Developments

Cerecor gets FDA fast track designation for CERC-802

Cerecor (NASDAQ:CERC) received FDA fast track designation for CERC-802 for the treatment of mannose-phosphate isomerase deficiency, also known as CDG-1b. CDG-1b is a rare genetic disease that impacts carbohydrate...

August 21, 2019

Author - Abby Hardy

Salarius Pharma names Scott Jordan as CBO; Mark Rosenblum as EVP finance and interim CFO

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Adamas Pharma names Neil McFarlane as CEO

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

Raymond James starts Profound Medical at OP; PT $4

Dawson James starts Athersys at buy; PT $11

Eiger gets FDA breakthrough therapy designation for HDV drug candidate

Cerecor gets FDA fast track designation for CERC-802

Subscribe